These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 15688598)

  • 1. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
    Schwartz R; Davidson T
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
    Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

  • 9. The potential role of proteasome inhibitors in the treatment of lung cancer.
    Bunn PA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4263s-4265s. PubMed ID: 15217971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
    Jackson G; Einsele H; Moreau P; Miguel JS
    Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma.
    Ogawa Y; Tobinai K; Ogura M; Ando K; Tsuchiya T; Kobayashi Y; Watanabe T; Maruyama D; Morishima Y; Kagami Y; Taji H; Minami H; Itoh K; Nakata M; Hotta T
    Cancer Sci; 2008 Jan; 99(1):140-4. PubMed ID: 17970782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, a newly approved proteasome inhibitor for the treatment of multiple myeloma: nursing implications.
    Colson K; Doss DS; Swift R; Tariman J; Thomas TE
    Clin J Oncol Nurs; 2004 Oct; 8(5):473-80. PubMed ID: 15515281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Hellmann A; Rule S; Walewski J; Shpilberg O; Feng H; van de Velde H; Patel H; Skee DM; Girgis S; Louw VJ
    Clin Pharmacokinet; 2011 Dec; 50(12):781-91. PubMed ID: 22087865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitors].
    Alexandre J
    Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review. Clinical pharmacokinetics of bortezomib.
    Levêque D; Carvalho MC; Maloisel F
    In Vivo; 2007; 21(2):273-8. PubMed ID: 17436576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.